ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer compound goes to Biogen

by Lisa M. Jarvis
March 19, 2018 | APPEARED IN VOLUME 96, ISSUE 12

Biogen will pay $75 million for the rights to Pfizer’s AMPA receptor potentiator PF-04958242. The first-in-class compound is meant to address cognitive impairment associated with schizophrenia by improving synaptic transmission. Biogen plans to begin a Phase IIb study of the compound later this year. This sale is the first to be announced since Pfizer said in January that it would end preclinical and early-stage neuroscience drug development.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment